Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122030 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
A Phase 2 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01122030 is a Phase 2 study that has completed, run by Shionogi. The registered enrollment target is 72 participants.
The verdict
NCT01122030, a Phase 2 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.
Interventions
- DRUG Placebo
- DRUG Naldemedine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-05-19 |
| Est. Completion | 2011-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01122030
The ClinicalTrials.gov registry entry for NCT01122030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01122030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01122030 about?
NCT01122030 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain". The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.
What is the current status of trial NCT01122030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2010-05-19. Estimated completion is 2011-03-22.
What interventions are being tested in trial NCT01122030?
The interventions under investigation include: Placebo (DRUG), Naldemedine (DRUG).
Who is sponsoring clinical trial NCT01122030?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.